See more : Grupo Empresarial San José, S.A. (GSJ.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Eterna Therapeutics Inc. (BTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eterna Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Changchai Company, Limited (200570.SZ) Income Statement Analysis – Financial Results
- LANXESS Aktiengesellschaft (LNXSY) Income Statement Analysis – Financial Results
- Bemax Inc. (BMXC) Income Statement Analysis – Financial Results
- Stanley Black & Decker, Inc. (0L9E.L) Income Statement Analysis – Financial Results
- LifePoint, Inc. (LFPI) Income Statement Analysis – Financial Results
Eterna Therapeutics Inc. (BTX)
About Eterna Therapeutics Inc.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 68.00K | 0.00 | 0.00 | 0.00 | 19.81M | 23.34M | 21.27M | 22.31M | 24.52M |
| Cost of Revenue | 236.00K | 497.00K | 459.00K | 98.00K | 7.84M | 8.39M | 7.09M | 8.13M | 13.06M |
| Gross Profit | -168.00K | -497.00K | -459.00K | -98.00K | 11.96M | 14.95M | 14.19M | 14.18M | 11.46M |
| Gross Profit Ratio | -247.06% | 0.00% | 0.00% | 0.00% | 60.40% | 64.07% | 66.68% | 63.55% | 46.74% |
| Research & Development | 5.92M | 10.39M | 12.71M | 3.95M | 26.00K | 72.00K | 139.00K | 0.00 | 0.00 |
| General & Administrative | 14.59M | 16.84M | 14.72M | 3.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.59M | 16.84M | 14.72M | 3.30M | 13.15M | 14.41M | 15.45M | 16.46M | 18.06M |
| Other Expenses | 461.00K | -1.17M | 899.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 20.73M | 27.23M | 27.43M | 7.25M | 13.18M | 14.49M | 15.59M | 16.46M | 18.06M |
| Cost & Expenses | 21.20M | 27.23M | 27.43M | 7.25M | 21.02M | 22.87M | 22.68M | 24.59M | 31.12M |
| Interest Income | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K |
| Interest Expense | 614.00K | 30.00K | 74.00K | 43.00K | 249.00K | 389.00K | 498.00K | 576.00K | 484.00K |
| Depreciation & Amortization | 1.12M | 497.00K | 459.00K | 98.00K | 3.17M | 2.76M | 2.32M | 2.89M | 3.10M |
| EBITDA | -19.93M | -33.22M | -121.95M | -7.15M | 1.96M | 3.23M | 915.00K | 609.00K | -3.63M |
| EBITDA Ratio | -29,314.71% | 0.00% | 0.00% | 0.00% | 9.88% | 13.83% | 4.30% | 2.73% | -14.26% |
| Operating Income | -21.14M | -33.22M | 68.34M | -7.25M | -1.21M | 464.00K | -1.40M | -2.28M | -6.60M |
| Operating Income Ratio | -31,080.88% | 0.00% | 0.00% | 0.00% | -6.12% | 1.99% | -6.59% | -10.21% | -26.92% |
| Total Other Income/Expenses | -536.00K | 8.68M | -95.05M | -19.28M | -808.00K | -787.00K | 391.00K | -607.00K | -614.00K |
| Income Before Tax | -21.67M | -24.53M | -122.30M | -7.29M | -2.02M | -323.00K | -1.01M | -2.89M | -7.21M |
| Income Before Tax Ratio | -31,869.12% | 0.00% | 0.00% | 0.00% | -10.20% | -1.38% | -4.75% | -12.93% | -29.42% |
| Income Tax Expense | -3.00K | 45.00K | 5.00K | -19.20M | 27.00K | -64.00K | 66.00K | 38.00K | 12.00K |
| Net Income | -21.67M | -24.58M | -122.31M | 11.91M | -2.05M | -259.00K | -1.08M | -2.92M | -7.23M |
| Net Income Ratio | -31,864.71% | 0.00% | 0.00% | 0.00% | -10.34% | -1.11% | -5.06% | -13.10% | -29.47% |
| EPS | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| EPS Diluted | -4.08 | -8.06 | -56.49 | 27.08 | -28.48 | -3.85 | -17.64 | -61.44 | -157.26 |
| Weighted Avg Shares Out | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
| Weighted Avg Shares Out (Dil) | 5.31M | 3.05M | 2.17M | 439.70K | 71.88K | 67.20K | 61.05K | 47.58K | 45.95K |
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning
Investors getting ready for another busy day of trading need to make sure they know the biggest pre-market stock movers before markets open. The post Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning appeared first...
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime
BioTime, Inc. to Announce Second Quarter 2017 Results on August 2, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release second quarter financial and operating results on Wednesday, August 2, 2017, after the close of the...
BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will report the top line data from the Company’s Renevia European pivotal trial, before the US market open...
BioTime, Inc. to Announce First Quarter 2017 Results on May 10, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release first quarter financial and operating results on Wednesday, May 10, 2017, after the close of the U.S....
BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on Thursday, March 16, 2017, after the close...
Source: https://incomestatements.info
Category: Stock Reports